Evaluation of miR-196a2 expression and Annexin A1 level in children with bronchial asthma Evaluation of miR-196a2 expression and Annexin A1 level in children

Main Article Content

A.A. Ibrahim
A. Ramadan
A.A. Wahby
I.H. Draz
N.R. El Baroudy
T.A. Abdel Hamid

Keywords

Annexin A1, miR-196a2, Bronchial asthma, Asthmatic children

Abstract

Background: Annexin A1 (ANXA1) is an important anti-inflammatory mediator that may play a significant role in bronchial asthma. MiR-196a2 can target ANXA1 and therefore may play a role in the pathogenesis of asthma.


Aim of study: This is the first study which aimed to evaluate the expression of miR-196a2 in the serum of asthmatic children and correlate its expression with ANXA1 serum level and asthma severity.


Subjects and methods: The study included 100 asthma patients who were subdivided into three groups (mild, moderate and severe) and 50 healthy control subjects. Assessment of miR-196a2 expression and ANXA1 serum level were done using quantitative reverse transcriptase PCR (RT qPCR) and Elisa techniques, respectively.


Results: Compared to the control group, asthmatic children showed an increased ANXA1 serum level and decreased expression of miR-196a2 (p = 0.001). However, ANXA1 serum level was lower and miR-196a2 expression was higher in severe asthmatic patients compared to moderate asthmatic ones (p = 0.01, 0.03). Pearson’s correlation coefficient revealed no significant correlations between ANXA1 serum level and miR-196a2 expression in the patient group (p = 0.9).


Conclusions: Altered miR-196a2 expression and serum ANXA1 concentration may play a role in the pathogenesis of asthma. In addition, ANXA1 and miR-196a2 may represent potential diagnostic biomarkers for asthma and future targets for therapy.

Abstract 140 | PDF Downloads 92

References

1. Kho AT, McGeachie MJ, Moore KG, Sylvia JM, Weiss ST, Tantisira KG. Circulating microRNAs and prediction of asthma exacerbation in childhood asthma. Respir Res. 2018;19:128, http://dx.doi.org/10.1186/s12931-018-0828-6.

2. Hussein MH, Toraih EA, Aly NM, Riad E, Fawzy MS. A passenger strand variant in miR-196a2 contributes to asthma severity in children and adolescents: a preliminary study. Biochem Cell Biol. 2016;94:347-57, http://dx.doi.org/10.1139/bcb-2016-0010.

3. Luthra R, Singh RR, Luthra MG, Li YX, Hannah C, Romans AM, et al. MicroRNA-196a targets annexin A1: a microRNA-mediated mechanism of annexin A1 downregulation in cancers. Oncogene. 2008;27:6667-78, http://dx.doi.org/10.1038/onc.2008.256.

4. Trinh HKT, Pham DL, Kim SC, Kim RY, Park HS, Kim SH. Association of the miR-196a2, miR-146a, and miR-499 polymorphisms with asthma phenotypes in a Korean population. Mol Diagn Ther. 2017;21:547-54, http://dx.doi.org/10.1007/s40291-017-0280-1.

5. Lee SH, Lee PH, Kim BG, Seo HJ, Baek AR, Park JS, et al. Annexin A1 in plasma from patients with bronchial asthma: its association with lung function. BMC Pulm Med. 2018;18:1, http://dx.doi.org/10.1186/s12890-017-0557-5.

6. Zhu J, Yue H, Qiao C, Li Y. Association between single-nucleotide polymorphism (SNP) in miR-146a, miR-196a2, and miR-499 and risk of ischemic stroke: a meta-analysis. Med Sci Monit. 2015;21:3658-63, http://dx.doi.org/10.12659/MSM.895233.

7. Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention; 2016. http://www.ginasthma.org/ [accessed 15.11.12].

8. Eke Gungor H, Tahan F, Gokahmetoglu S, Saraymen B. Decreased levels of lipoxin A4 and annexin A1 in wheezy infants. Int Arch Allergy Immunol. 2014;163:193-7, http://dx.doi.org/10.1159/000358490.

9. Cho SH, An HJ, Kim KA, Ko JJ, Kim JH, Kim YR, et al. Single nucleotide polymorphisms at miR-146a/196a2 and their primary ovarian insufficiency-related target gene regulation in granulosa cells. PLoS ONE. 2017;12:e0183479.

10. Fawzy MS, Toraih EA, Ibrahiem A, Abdeldayem H, Mohamed AO, Abdel-Daim MM. Evaluation of miRNA-196a2 and apoptosis related target genes: ANXA1, DFFA and PDCD4 expression in gastrointestinal cancer patients: a pilot study. PLoS One. 2017;12:e0187310.

11. Toraih EA, Fawzy MS, Mohammed EA, Hussein MH, ElLabban MM. MicroRNA-196a2 biomarker and targetome network analysis in solid tumors. Mol Diagn Ther. 2016;20:559-77, http://dx.doi.org/10.1007/s40291-016-0223-2.

12. Guo C, Liu S, Sun MZ. Potential role of Anxa1 in cancer. Future Oncol. 2013;9:1773-93, http://dx.doi.org/10.2217/fon.13.114.

13. Álvarez-Teijeiro S, Menéndez ST, Villaronga MÁ, PenaAlonso E, Rodrigo JP, Morgan RO, et al. Annexin A1 down-regulation in head and neck squamous cell carcinoma is mediated via transcriptional control with direct involvement of miR-196a/b. Sci Rep. 2017;7:6790, http://dx.doi.org/10.1038/s41598-017-07169-w.

14. Masaki T, Tokuda M, Ohnishi M, Watanabe S, Fujimura T, Miyamoto K, et al. Enhanced expression of the protein kinase substrate annexin in human hepatocellular carcinoma. Hepatology. 1996;24:72-81.

15. Anbalagan D, Yap G, Yuan Y, Pandey VK, Lau WH, Arora S, et al. Annexin-A1 regulates MicroRNA-26b* and MicroRNA-562 to directly target NF-B and angiogenesis in breast cancer cells. PLoS ONE. 2014;9:e114507 https://doi.org/10.1371/journal.pone.0114507

16. Yuan Y, Anbalagan D, Lee LH, et al. ANXA1 inhibits miRNA-196a in a negative feedback loop through NF-kB and c-Myc to reduce breast cancer proliferation. Oncotarget. 2016;7:27007-20.

17. Kang JS, Calvo BF, Maygarden SJ, Caskey LS, Mohler JL, Ornstein DK. Dysregulation of annexin I protein expression in high-grade prostatic intraepithelial neoplasia and prostate cancer. Clin Cancer Res. 2002;8:117-23.

18. Smith SF, Tetley TD, Guz A, Flower RJ. Detection of lipocortin 1 in human lung lavage fluid: lipocortin degradation as a possible proteolytic mechanism in the control of inflammatory mediators and inflammation. Environ Health Perspect. 1990;85:135-44, http://dx.doi.org/10.2307/3430676.

19. Vishwanatha JK, Davis RG, Rubinstein I, Floreani A. Annexin I degradation in bronchoalveolar lavage fluids from healthy smokers: a possible mechanism of inflammation. Clin Cancer Res Clin Cancer Res. 1998;4:2559-64.

20. Ferlazzo V, D’Agostino P, Milano S, Caruso R, Feo S, Cillari E, et al. Anti-inflammatory effects of annexin1: stimulation of IL-10 release and inhibition of nitric oxide synthesis. Int Immunopharmacol. 2003;3:1363-9, http://dx.doi.org/10.1016/S1567-5769(03)00133-4.

21. Parente L, Solito E. Annexin 1: more than an antiphospholipase protein. Inflamm Res. 2004;53:125-32, http://dx.doi.org/10.1007/s00011-003-1235-z.

22. Eke Gungor H, Tahan F, Gokahmetoglu S, Saraymen B. Decreased levels of lipoxin A4 and annexin A1 in wheezy infants. Int Arch Allergy Immunol. 2014;163:193-7, http://dx.doi.org/10.1159/000358490.

23. Ng FS, Wong KY, Guan SP, Mustafa FB, Kajiji TS, Bist P, et al. Annexin-1 deficient mice exhibit spontaneous airway hyperresponsiveness and exacerbated allergen-specific antibody responses in a mouse model of asthma. Clin Exp Allergy. 2011;41:1793-803,
http://dx.doi.org/10.1111/j.1365-2222.2011.03855.x.

24. El-Mashad GM, Mahmoud AA, Abdel Hafez AA. The prevalence of bronchial asthma among primary school children in Menoufiya Governorate (El-Bagour Center). Menouf Med J. 2016;29:89-94.